The Imaging Innovation Center hits a milestone

The Max Delbrück Center, Berlin, celebrates its new, innovative research building with a “topping-out ceremony.” The Imaging Innovation Center, designed by the architectural firm heinlewischer, will host researchers specializing in imaging and…

3 Min
More

Interview | Tim Huse, Head of BIH Digital Health Accelerator, Berlin Institute of Health @ Charité (BIH)

Berlin-Brandenburg: an international start-up hotspot in the digital health segment

6 Min
More

Mechanism of phosphorylation in Trek channels offers therapeutical potential

A team led by Prof. Dr. Han Sun from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) has elucidated an important mechanism in the function of TREK channels at an atomic level. The results, published in the journal "Nature…

3 Min
More

Claudia Langenberg elected as EMBO member

The European Molecular Biology Organization (EMBO) has elected Professor Claudia Langenberg of the Berlin Institute of Health at Charité (BIH), and of the Precision Healthcare University Research Institute (PHURI) at Queen Mary University of London,…

3 Min
More

New center of excellence for single cell omics

On July 8, the Max Delbrück Center and Bruker will kick off a strategic partnership to build a first-of-its-kind innovation hub for systems medicine. The new center will focus on the development and application of mass spectrometry based single-cell…

6 Min
More

GIANT WITH A CERAMIC HEART

A new NMR spectrometer has been in operation at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) since the end of May. What makes it special is that it is based on a new type of ceramic high-temperature superconductor. Peter…

4 Min
More

Does a Mixture of One Million Peptides Hold the Key to the Antibiotics of the Future?

New approach to diminish antibiotic resistance developed by research team from Freie Universität Berlin, the Hebrew University of Jerusalem, and ETH Zurich

2 Min
More

Scientists unravel life-saving effect of dexamethasone in COVID-19

Dexamethasone is one of the most important drugs in the treatment of severe COVID-19, but patients respond very differently to the therapy. Researchers at Charité – Universitätsmedizin Berlin and the German Center for Neurodegenerative Diseases…

4 Min
More

Pentixapharm Acquires Target Discovery Business of Glycotope

Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range of malignancies, has announced the execution of an agreement, effective July 1st, to acquire the target discovery…

4 Min
More

Charité intensifies cooperation with CLALIT Health Services

During the COVID-19 pandemic, Israel impressively demonstrated how efficient patient data collection can be used to advance research into the prevention of infections and development of therapies. One of Israel's largest healthcare organizations,…

4 Min
More
Show more items